Bristol-Myers Squibb Company (BMY) Stock Price, Quote & News

Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 609 252 4621

Website: www.bms.com

Address:

Route 206 & Province Line Road, Princeton, United States

eliseocolon Jun. 20 at 6:32 PM

$BMY

0 · Reply

taxplanr Jun. 20 at 3:34 PM

Another amazing Breast cancer treatment success with Ivermectin Fenbendazole and Methylene Blue $BNTX $CVAC $BMY $MRNA https://makismd.substack.com/p/ivermectin-and-fenbendazole-and-methylene?utm_source=post-email-title&publication_id=1385328&post_id=166377262&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email

1 · Reply

JDR1983 Jun. 20 at 3:12 PM

$BMY $CRSP buying shares.

0 · Reply

JDR1983 Jun. 20 at 2:56 PM

$BMY added more.

0 · Reply

complexoptions Jun. 20 at 1:52 PM

$BMY what a mistake to buy this

0 · Reply

ZacksResearch Jun. 20 at 1:11 PM

$PFE vs. $BMY — Which oncology play wins right now? Pfizer’s broader portfolio and higher dividend yield tilt the scale in its favor in the current setup. Full breakdown here 👉 https://www.zacks.com/stock/news/2520352/pfizer-vs-bmy-which-oncology-drugmaker-is-a-better-choice-for-now?cid=sm-stocktwits-2-2520352-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2520352_TEASER?cid=sm-stocktwits-2-2520352-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2520352_TEASER

0 · Reply

NYC100 Jun. 19 at 10:30 PM

$BMY $GILD $MRK $NUVB $PFE it has happened to me before I sold a stock because this seeking Alpha wrote a bad article and after I sold it, the stock went up 100% or more 😂😂

0 · Reply

JDR1983 Jun. 19 at 7:37 PM

$BMY Bought 2,000 shares.

0 · Reply

BiotechBonesaw Jun. 19 at 2:52 PM

$NUVB I read thru the seeking alpha article after @BioCapitalist99 alerted me - it’s hogwash. Phase 4 studies are often required, and the first one for pediatric cancer is good news on multiple fronts. There aren’t many children with ROS1+ NSCLC (thank God), but that trial should extend Ibtrozi’s patents. They also didn’t check LinkedIn. The sales force at Nuvation is great - many are friends from my Celgene days prior to our acquisition by $BMY . Quite a few of them were at Medivation & Immunomedics prior to their acquisitions as well (by $PFE & $GILD , respectively). I currently own a little over 11K shares and will likely buy more if it stays this cheap. Hung won’t sell this for $14B like Medivation, but Ibtrozi is worth a couple of billion to a large pharma buyer - most likely not $MRK (although they need to be cutting deals left and right before Keytruda faces LOE. I’m a Nuvation bull 🐂 And this Seeking Alpha article is 🐂 💩 Good Luck to my fellow Bulls! ☘️

1 · Reply

Wallst45 Jun. 19 at 11:13 AM

$MDGL As per WF, $MDGL likely to be acquired by $BMY

0 · Reply

I'm Buying Dividend Giants At Huge Discounts

ABBV CVX OXY PFE SHEL SLB TTE

Jun 17, 2025, 4:16 PM EDT - 3 days ago

Bristol Myers Squibb Announces Dividend

Jun 16, 2025, 6:59 AM EDT - 5 days ago

Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)

Jun 12, 2025, 9:00 AM EDT - 9 days ago

Dividend Harvesting Portfolio Week 223: $22,300 Allocated, $2,310.77 In Projected Dividends

ARE JEPI MO PDI QQQI VICI

Jun 12, 2025, 6:59 AM EDT - 9 days ago

Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025

Jun 12, 2025, 6:45 AM EDT - 9 days ago

Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025

Jun 11, 2025, 1:43 PM EDT - 9 days ago

Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)

Jun 11, 2025, 6:59 AM EDT - 10 days ago

Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis

Jun 10, 2025, 5:55 PM EDT - 10 days ago

Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties

Jun 10, 2025, 12:47 PM EDT - 10 days ago

5 Ideal 'Safe' Buys From June Fortune Return On Leadership Screen

ACI CMCSA COP CVS CVX EPD ET

Jun 6, 2025, 7:00 AM EDT - 15 days ago

Bristol-Myers And BioNTech Deal: Good For Both Parties, But One Is The Better Investment

BNTX

Jun 3, 2025, 3:34 PM EDT - 17 days ago

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO

AZN GILD PFE AMGN BNTX MRK

Jun 2, 2025, 3:50 PM EDT - 18 days ago

Bristol Myers CEO explains why he's spending billions on BioNTech deal

BNTX

Jun 2, 2025, 2:51 PM EDT - 18 days ago

Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz

BNTX BPMC MRK SNY

Jun 2, 2025, 12:22 PM EDT - 18 days ago

Bristol Myers Squibb CEO on $11B cancer drug deal with BioNTech

BNTX

Jun 2, 2025, 11:08 AM EDT - 19 days ago

Bristol Myers CEO on Biontech deal: Next new frontier in treatment of cancer

BNTX

Jun 2, 2025, 8:46 AM EDT - 19 days ago

Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race

BNTX

Jun 2, 2025, 7:42 AM EDT - 19 days ago

BioNTech Sets Cancer-Drug Deal With Bristol Myers Squibb

BNTX

Jun 2, 2025, 6:50 AM EDT - 19 days ago

Bristol Myers to pay $1.5 billion upfront for BioNTech cancer drug partnership

BNTX

Jun 2, 2025, 6:45 AM EDT - 19 days ago

BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types

May 28, 2025, 6:50 PM EDT - 23 days ago

Bristol-Myers Squibb Company (BMY) Bernstein 41st Annual Strategic Decisions Conference (Transcript)

May 28, 2025, 10:07 AM EDT - 24 days ago

Bristol-Myers Squibb's Painful Pullback Has Triggered Richer Dividend Story - Upgrade To Buy

May 28, 2025, 6:59 AM EDT - 24 days ago

Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 28, 2025, 6:55 AM EDT - 24 days ago

Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications

May 27, 2025, 4:42 PM EDT - 24 days ago

Bristol-Myers Squibb: This Undervalued Dog Needs An Option Collar

May 27, 2025, 12:16 PM EDT - 24 days ago

Bristol-Myers: Among The Cheapest Pharma Names, Now Yielding Above 5%

May 27, 2025, 9:14 AM EDT - 25 days ago

Bristol-Myers Squibb At ASCO 2025: A Resilient Play Amid Market Turbulence

May 26, 2025, 11:45 AM EDT - 25 days ago

When It Rains Gold, Put Out The Bucket: 2 Wonderful Income Bargains

REXR

May 23, 2025, 8:15 AM EDT - 4 weeks ago

Avoid These Dividend Disasters Before It's Too Late

AMGN COP CVS CVX DLR GNL HD

May 22, 2025, 5:05 PM EDT - 4 weeks ago

Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline

May 21, 2025, 4:20 PM EDT - 4 weeks ago

Buy 9 Barron's Better Bets (Than T-Bills) From 16 'Safer' May Dividend Dogs

BBY CAG ETR FRT KIM LYB MO

May 21, 2025, 6:59 AM EDT - 4 weeks ago

Bristol Myers Squibb to Participate in the Bernstein 41st Annual Strategic Decisions Conference

May 19, 2025, 1:00 PM EDT - 4 weeks ago

Buy These 2 Beaten Down Stocks Now Before They Rally

AAT ARE PFE

May 18, 2025, 8:35 AM EDT - 4 weeks ago

5 Dirt-Cheap Dividends Paying Up To 7.6%

AES AESI DINO PII

May 16, 2025, 6:59 AM EDT - 5 weeks ago

Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with PD-L1 Expression ≥1%

May 15, 2025, 6:27 PM EDT - 5 weeks ago

Final Trade: RIO, FCX, X, BMY

FCX RIO X

May 14, 2025, 8:00 PM EDT - 5 weeks ago

Jim Cramer talks good companies getting pummeled by rising interest rates

ABBV CL GM JNJ PEP PG

May 12, 2025, 12:30 PM EDT - 5 weeks ago

Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet

ABBV AMGN BIIB GILD JNJ LLY MRK

May 9, 2025, 8:35 PM EDT - 6 weeks ago

Hawaii in $700 million settlement with Bristol-Myers, Sanofi over Plavix warning label

SNY

May 8, 2025, 7:23 PM EDT - 6 weeks ago

Pressure is still on the pharma sector, says Mizuho's Jared Holz

ABBV AMGN GILD JNJ LLY MRK NVO

May 8, 2025, 9:00 AM EDT - 6 weeks ago

Dividend Harvesting Portfolio Week 218: $21,800 Allocated, $2,195.04 In Projected Dividends

BP BTI MO PFE SLG

May 6, 2025, 6:59 AM EDT - 6 weeks ago

Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer

May 5, 2025, 5:23 PM EDT - 6 weeks ago

Bristol Myers to invest $40 billion in the US over 5 years, CEO says

Apr 28, 2025, 7:16 AM EDT - 7 weeks ago

Top 3 Health Care Stocks That May Rocket Higher In April

UNH XFOR

Apr 28, 2025, 7:15 AM EDT - 7 weeks ago

Retirement Strategy: 2 Blue Chip Dividends Now Way Too Cheap

Apr 25, 2025, 6:06 PM EDT - 2 months ago

We're in a pharma stock pickers market, says Kessef's Len Yaffe

ABBV GILD JNJ LLY MRK PFE REGN

Apr 25, 2025, 10:27 AM EDT - 2 months ago

5 Positives From Bristol-Myers Squibb's Q1 2025 Results

Apr 25, 2025, 9:53 AM EDT - 2 months ago

Exclusive: US pharma tariffs would raise US drug costs by $51 bln annually, report finds

AMGN LLY PFE

Apr 25, 2025, 9:00 AM EDT - 2 months ago

Bristol-Myers: Undervalued, Delivering Increased 2025 Guidance

eliseocolon Jun. 20 at 6:32 PM

$BMY

0 · Reply

taxplanr Jun. 20 at 3:34 PM

1 · Reply

JDR1983 Jun. 20 at 3:12 PM

$BMY $CRSP buying shares.

0 · Reply

JDR1983 Jun. 20 at 2:56 PM

$BMY added more.

0 · Reply

complexoptions Jun. 20 at 1:52 PM

$BMY what a mistake to buy this

0 · Reply

ZacksResearch Jun. 20 at 1:11 PM

0 · Reply

NYC100 Jun. 19 at 10:30 PM

$BMY $GILD $MRK $NUVB $PFE it has happened to me before I sold a stock because this seeking Alpha wrote a bad article and after I sold it, the stock went up 100% or more 😂😂

0 · Reply

JDR1983 Jun. 19 at 7:37 PM

$BMY Bought 2,000 shares.

0 · Reply

BiotechBonesaw Jun. 19 at 2:52 PM

1 · Reply

Wallst45 Jun. 19 at 11:13 AM

$MDGL As per WF, $MDGL likely to be acquired by $BMY

0 · Reply

MF__DOOM Jun. 19 at 2:33 AM

$BMY struggle with the $50 last time but I like the v

0 · Reply

onestudy Jun. 19 at 12:58 AM

$CPHI A major investment research firm named CPHI as one of the few pharmaceutical companies licensed to manufacture Cerebroprotein Hydrolysate — a CNS (central nervous system) drug used to treat Alzheimer’s disease, stroke, Parkinson’s-related dementia, and brain injury. I was surprised to learn this drug is actually derived from pig brain. I didn’t expect that — but it turns out many major pharma companies also use animal-derived ingredients. For example: 🐷 $PFE produces blood thinners (heparin) from pig intestines 🧬 $ABBV uses pig pancreas enzymes to treat pancreatic disorders 💉 $NVO developed early insulin treatments from pig and cow pancreases 🧫 $BMY uses animal cells in biologics and antibody drug development Animal-based biotech is more common than people think and CPHI is part of that landscape.

0 · Reply

Quantumup Jun. 18 at 8:44 PM

William Blair🏁 $CTNM Outperform-$23.26 and said, "We are initiating coverage of Contineum Therapeutics with an Outperform rating and fair value of $23.26 per share." $BMY $JNJ $TGTX RHHBY $AXSM LLY PFE ABBV GSK TAK William Blair went on to say:

0 · Reply

Wallst45 Jun. 18 at 8:12 PM

$BMY they need to acquire growth companies

0 · Reply

DonCorleone77 Jun. 18 at 8:11 PM

$PRTA $NVO $BMY Prothena announces corporate restructuring, cuts 63% of workforce Prothena (PRTA) "announced that the company has initiated an approximate 63% reduction in its workforce to substantially reduce its operating costs to those necessary to support its remaining wholly owned programs, its obligations to partnered programs, and its anticipated business development activities. The board, management, and Company's financial advisors are collectively evaluating a comprehensive range of business options to best serve the interest of its shareholders that consider the implications of multiple recent and upcoming milestones, including: Earlier this week Roche announced that it will advance prasinezumab into Phase 3 development for early-stage Parkinson's disease; Company expects initial data in August from Phase 1 ASCENT clinical trials of its wholly owned PRX012 program in Alzheimer's disease; Novo Nordisk (NVO) expects to share data from its Phase 2 clinical trial evaluating coramitug for ATTR-CM in the second half of 2025; Company expects to complete a Phase 1 clinical trial for PRX019 in collaboration with Bristol Myers Squibb (BMY) in 2026; Bristol Myers Squibb expects to complete a Phase 2 TargetTau-1 clinical trial evaluating BMS-986446 in Alzheimer's disease in 2027; Company has potential to receive up to $105 million in 2026 for clinical milestones from various partnered programs."

0 · Reply

taxplanr Jun. 18 at 5:46 PM

Ivermectin and Menbendazole cure Breast cancer $BNTX $CVAC $BMY $MRNA https://makismd.substack.com/p/ivermectin-and-mebendazole-testimonial-3f0?utm_campaign=email-half-post&r=18m8lm&utm_source=substack&utm_medium=email

1 · Reply

swingingtech Jun. 18 at 4:45 PM

$THO $DELL $BMY $LNG https://wallstreetwaves.com/dividend-insights-tho-dell-bmy-lng-mitt/

0 · Reply

Duediligence20 Jun. 18 at 3:12 PM

$BMY Company is the most strategically unfit company in Pharma. Pathetic performance and nothing coming immediately in the way of help!

0 · Reply

FinTrackh Jun. 18 at 2:20 PM

$BMY .

0 · Reply

Hotresearchsgoldenage Jun. 18 at 12:05 PM

$BMY cures bladder cancer at 80 percent success rate. Shipping meds in July 21,500 per treatment. Only cure for bladder cancer !

0 · Reply

SeniorVip Jun. 18 at 5:27 AM

$IBRX $AMGN $LLY $BMY

0 · Reply

BlueQuant Jun. 17 at 9:04 PM

$BMY Declares a quarterly dividend of $0.62 per share on common stock. https://www.gurufocus.com/news/2932388/bristol-myers-squibb-announces-dividend-bmy-stock-news

0 · Reply

Market Cap	95.32B
Revenue (ttm)	48.30B
Net Income (ttm)	-8.95B
EPS (ttm)	N/A
PE Ratio	6.43
Forward PE	6.93
Profit Margin	-18.53%
Debt to Equity Ratio	2.85

Volume	47,287,200
Avg Vol	15,857,076
Day's Range	N/A - N/A
Shares Out	2.04B
Stochastic %K	11%
Beta	0.38
Analysts	Sell
Price Target	$56.14